ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
-0,49%
Bitcoin
66.201,00
0,30%
Brent Oil
82,275
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) Notícias

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RARE
DataHoraFonteTítuloCódigoCompanhia
14/06/202418:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RAREUltragenyx Pharmaceutical Inc
13/06/202421:49GlobeNewswire Inc.Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202420:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202418:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202417:05GlobeNewswire Inc.Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202417:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202417:00GlobeNewswire Inc.Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
11/06/202418:47GlobeNewswire Inc.Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
04/06/202417:05GlobeNewswire Inc.Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/05/202417:00GlobeNewswire Inc.Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)NASDAQ:RAREUltragenyx Pharmaceutical Inc
17/05/202417:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
07/05/202417:30GlobeNewswire Inc.Ultragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
02/05/202417:00GlobeNewswire Inc.Ultragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202417:00GlobeNewswire Inc.Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202409:00GlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
25/04/202417:30GlobeNewswire Inc.Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
15/04/202408:00GlobeNewswire Inc.Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102NASDAQ:RAREUltragenyx Pharmaceutical Inc
12/04/202417:22GlobeNewswire Inc.Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/04/202409:00GlobeNewswire Inc.Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
27/02/202418:30GlobeNewswire Inc.Ultragenyx to Participate at Investor Conferences in MarchNASDAQ:RAREUltragenyx Pharmaceutical Inc
21/02/202419:03Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RAREUltragenyx Pharmaceutical Inc
15/02/202418:01GlobeNewswire Inc.Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/02/202418:00GlobeNewswire Inc.Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/02/202410:00GlobeNewswire Inc.Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
05/02/202418:05GlobeNewswire Inc.Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
25/01/202418:05GlobeNewswire Inc.Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/01/202409:00GlobeNewswire Inc.Mereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/01/202413:00GlobeNewswire Inc.Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/01/202410:00GlobeNewswire Inc.Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)NASDAQ:RAREUltragenyx Pharmaceutical Inc
03/01/202410:00GlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RARE

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BOBR4
BOMBRIL PN
BOV
PRIO3
PETRORIO ON
BOV
OIBR3
OI ON
BOV
RENT3
LOCALIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados